Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Abstract

Thrombopoietin receptor agonists ( TPO ‐ RA s) are used as effective alternative treatments in ITP patients unresponsive to first‐/second‐line therapies. TPO ‐ RA s can also be used to normalize platelet count to safely perform invasive procedures and chemotherapy, in case of malignancies. In few responsive patients, TPO ‐ RA s can be suspended maintaining a sustained response.